Recent results suggest that tucatinib, when combined with trastuzumab and capecitabine, is effective in patients with locally advanced inoperable or metastatic HER2-positive breast cancer who have received prior therapies: In a phase II trial, the drug extended overall survival and progression-free survival compared with trastuzumab and capecitabine alone, and improved progression-free survival in patients with brain metastases.

中文翻译：

---

图卡替尼在乳腺癌中的疗效令人印象深刻。

最新研究结果表明，曲妥替尼联合曲妥珠单抗和卡培他滨治疗之前已接受过局部治疗的局部晚期无法手术或转移性HER2阳性乳腺癌患者有效：在一项II期临床试验中，该药物可延长总体生存期和无进展生存期与曲妥珠单抗和卡培他滨单独治疗相比，脑转移患者的无进展生存期得到了改善。